GSK's RSV Vaccine Arexvy Gets Positive CHMP Opinion For Adults Aged 50-59 At Increased Risk
29/7 08:28
(RTTNews) - GSK plc (GSK, GSK.L) announced Monday that its Respiratory Syncytial Virus or RSV vaccine, Arexvy, has received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP for adults aged 50-59 at increased risk for RSV...